Binimetinib showed clinical activity in a phase 2 study (NCT01320085), yielding a 15% response rate in patients with advanced NRAS-mutant melanoma (Ascierto et al, 2013; Van Herpen et al, 2015). Here, NRAS is linked to melanoma.